Lightnews — Scholar-powered news

Reposted by Graham Collins

Paul Bröckelmann @broeckelmann.bsky.social · Jul 8

3-year follow-up of TRANSFORM @ascocancer.bsky.social confirms significantly improved PFS with lisocel compared to SOC as second-line treatment for r/r LBCL (51% vs 26%): ascopubs.org/doi/10.1200/... PRO indicate improved HRQoL incl. Fatigue on treatment with lisocel, but similar long-term outcomes.

1 1 1

Graham Collins @graham74gc.bsky.social · Jul 8

Just about to give our first liso-cel doses so this is good to see!

2

Graham Collins @graham74gc.bsky.social · Jun 20

Fujimoto et al - Allo / auto in ENKT? Japanese data.
• if in CR, ASCT appear superior to allo
• if in PR, allo appears preferable
• no impact on source of allo cells
I normally allo these pts in CR1 so potentially practise changing.
#18ICML #ICML25 #lymsm

1

Graham Collins @graham74gc.bsky.social · Jun 20

Held et al - NIVEAU trial. Nivo-GemOx vs GemOx RR PTCL
• 76 pts part of bigger trial
• PFS no diff but was ⬆️ when MVA performed
• responses ⬆️
• BUT ⬆️ toxic incl ‘infn’ (?hyperinfl state instead); ⬆️ deaths.
Doubt there will be further development.
#18ICML #ICML25 #lymsm

1 4

Graham Collins @graham74gc.bsky.social · Jun 20

Patel: JNJ4496 (anti CD19/20 tandem CAR) RR DLBCL, 41BB costim
• global Ph 1B
• med age 72y
• at RP2D, ORR 100%, CRR 80%
• no G3+ CRS, 8% ICANs
Very impressive results
#18ICML #ICML25 #lymsm

2 6

Graham Collins @graham74gc.bsky.social · Jun 19

Dreyfuss et al
• ISRT & Pembro in localised relapsed cHL
• RT dose varied according to response to Pembro
• generally safe & good outcomes
• did not seem to impair subseq Rx
Consider for older relapsed pts
#18ICML #ICML25 #lymsm

1 3

Graham Collins @graham74gc.bsky.social · Jun 19

Dreyfuss et al
• ISRT & Pembro in localised relapsed cHL
• RT dose varied according to response to Pembro
• generally safe & good outcomes
• did not seem to impair subseq Rx
Consider for older relapsed pts
#18ICML #ICML25 #lymsm

Graham Collins @graham74gc.bsky.social · Jun 19

Davison et al - PRO substudy of S1826 substudy. Interesting outputs:
• NivoAVD showed more fatigued compared with BV-AVD on treatment but did not meet ‘clin significant’ threshold.
• BV-AVD showed excess neuropathy which had a clinically meaningful impact.
#ICML25 #lymsm

1

Graham Collins @graham74gc.bsky.social · Jun 19

Evans et al: E-HIPI prognostic score early cHL
• Holistic consortium
• 1 binary factor: female sex better prog
• 3 continuous: max tumour diam, Hb and albumin. Great work from

Online calculator now available!
#18ICML #ICML25 #lyms

Graham Collins @graham74gc.bsky.social · Jun 19

Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but interesting assocn seen between regional difference in dox use and outcome.

Take home message: if safe to use dox then do use it!

#18ICML #ICML25 #lymsm

2

Graham Collins @graham74gc.bsky.social · Jun 19

Lewis et al - MRD analysis in ENRICH: IR vs R-chemo in 1L MCL
• flow cytometry based
• MRD- most rapid with BR
• with RCHOP, even MRD- pts do poorly
• with IR, no assocn with MRD & outcome
#18ICML #ICML25 #lymsm

Graham Collins @graham74gc.bsky.social · Jun 19

Flerlage et al
• GLOW data nod LPHL
• completely resected 1A, RT assoc with ⬆️ PFS compared with observation
• unresected - ABVD-RT & RT do v well
• no infield relapses if RT given
Great work which significantly informs practice. #18ICML #ICML25
#lymsm

Graham Collins @graham74gc.bsky.social · Jun 19

Rossi et al - baseline MTV, Dmax & esp combo, assoc with PFS.
Independent effect of IPSS.
Both factors improve prognostic impact of iPET.
Based on AHL2011 study so all have 2x eacBEACOPDac as 1st 2 cycle.
#18ICML #ICML25

1

Graham Collins @graham74gc.bsky.social · Jun 19

Herrera et al - ctDNA in S1826
• 97% ctDNA + baseline
• clearance at C3D1 assoc with PFS
• within pos pts, those with minor ⬇️ assoc with esp poor outcomes
• EOT ctDNA detection also assoc with poor outcomes
CtDNA ripe for response adapted trials.
#18ICML #ICML25 #lymsm

Graham Collins @graham74gc.bsky.social · Jun 19

Ahmed et al - EBV & cHL subtype in S1826 study
• EBV+ pts do much better with NAVD compared with BV-AVD (EBV- also do better but less marked)
• non-NS histology also benefited more from NAVD.
Biology is important!
#lymsm #18ICML #ICML25

Graham Collins @graham74gc.bsky.social · Jun 19

Things are hotting up for the first of 2 #Hodgkin lymphoma sessions today.
#18ICML #ICML25 #lymsm

1

Graham Collins @graham74gc.bsky.social · Jun 18

Ah shame - but perhaps not surprising.

Graham Collins @graham74gc.bsky.social · Jun 18

A no. of trials in RR DLBCL with RGemOx as comparator all show:
• PFS med 2-3 mo
• OS med 12-13 mo
Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc.

Beaten by exptl arms in StarGlo, Polargo, Sunmo

Take home: no more RGemOx pls - it’s defeated!
#18ICML #lymsm

1

Graham Collins @graham74gc.bsky.social · Jun 18

Feldman et al - acimtamig (CD16/CD30 engager) with alloNK in RR #Hodgkin
• 24 pts, heavily preRx
• ORR 88%, CRR 58%
• 25% CRS with 1 G3, no ICANs or GvH
Looks very active. Interested to see how it will developed further.
#18ICML

3

Graham Collins @graham74gc.bsky.social · Jun 18

Shah et al - Zamto-cel 3L+ DLBCL
• tandem CD19 / CD20 41BB construct
• non cryopreserved, short vein-vein
• 69 pts
• ORR 73%, CRR 51%
• no G3+ CRS, 4% G3+ ICANS
Clearly active but is it better than current agents?
#18ICML

1

Graham Collins @graham74gc.bsky.social · Jun 18

Sancho et al - POLARGO.
• RGemOx vs Pola-RGemOx R/R DLBCL
• 2L+ DLBCL (no ASCT eligible if 2L)
• OS primary EP: signif adv 12.5mo vs 19.5mo
• PFS & CMR rate better
• tox modest - ⬆️ infn & PN
• no effect of cell of origin
Interesting but ? value if 1L PolaRCHP
#18ICML

1 3

Graham Collins @graham74gc.bsky.social · Jun 18

Stathis et al - feasibility of PET & ctDNA response adaptation in 1L DLBCL.
• operationally deliverable with ctDNA turnaround median 9d
• low rate PET+ and ctDNA+ at interim
• assessing whether acala addition benefits those with Myd88 &/or CD79b mutns
SAKK38/19 trial #ICML18

2 4

Graham Collins @graham74gc.bsky.social · Jun 18

@dgermain21.bsky.social - fantastic work on LymphomaMAPs (microenv of DLBCL) looking at prognosis of CAR-T therapy. Showed that TEX archetype associated with signif worse outcome. Assoc with
• exhausted T-cells
• super-activated macrophages.
#ICML18

1 3

Graham Collins @graham74gc.bsky.social · Jun 18

The EBV results are striking. Do have any biological hypotheses as to why we see the difference Paul?

1 1

Graham Collins @graham74gc.bsky.social · Jun 18

Nivo-AVD vs BV-AVD in older pts (60+) with #Hodgkin. S1826 data. 99 eligible pts. 2y PFS
• 89% Nivo-AVD
• 64% BV-AVD
55% discontinued BV, 14% Nivo
NRM 16% BV-AVD, 6% Nivo-AVD
Transformational. If only we had access!
#lymsm

ascopubs.org/doi/10.1200/...

Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826

Older patients with classic Hodgkin lymphoma (cHL) have inferior survival compared with younger patients. We report a subset analysis of older patients (60 years and older) enrolled in the phase three...

ascopubs.org

3